What is the recommended dose and dosing interval of oral methylergometrine 0.125 mg tablet for postpartum uterine tone maintenance?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 11, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Methylergometrine 0.125 mg Tablet Dosing

The recommended dose of oral methylergometrine 0.125 mg tablet is one tablet three times daily for a maximum of one week postpartum, though the standard FDA-approved formulation is 0.2 mg tablets given 3-4 times daily. 1

Standard Dosing Regimen

  • The FDA-approved oral dose is 0.2 mg (one tablet) taken 3 or 4 times daily during the puerperium for a maximum of 1 week. 1

  • The 0.125 mg formulation represents a lower-strength tablet that was historically used at a dosing frequency of three times daily (t.i.d.) in clinical studies. 2, 3

  • Peak serum concentrations occur approximately 3 hours after oral administration in postpartum women, indicating delayed gastrointestinal absorption compared to non-pregnant individuals. 2

Clinical Context and Limitations

  • Methylergometrine is contraindicated in cardiovascular disease management during pregnancy and postpartum due to significant risk (>10%) of vasoconstriction and hypertension. 4

  • The European Society of Cardiology explicitly states that methylergonovine should not be used for postpartum hemorrhage prevention in women with cardiovascular conditions, as prostaglandin F analogues are safer alternatives unless pulmonary artery pressure elevation is undesirable. 4

  • For routine third-stage management, a single intramuscular dose of oxytocin is preferred over ergometrine derivatives, with ergometrine being contraindicated during active labor management. 4

Evidence Quality Concerns

  • Oral methylergometrine has demonstrated unfavorable pharmacokinetic properties with unpredictable absorption and no proven clinical effect on reducing postpartum blood loss compared to placebo. 5

  • A prospective randomized double-blind study of 217 women found no significant difference in lochia amount, analgesic requirements, or hospital stay duration between methylergometrine 0.125 mg three times daily and placebo when given for 72 hours postpartum. 3

  • The medication is unstable even under refrigerated conditions, raising concerns about its reliability in clinical practice, particularly in resource-limited settings. 5

Role in Uterine Atony Management

  • Methylergonovine serves as a highly effective second-line agent for treating established uterine atony when oxytocin fails, despite its severe potential side effects including vasoconstriction and hypertension. 6

  • Oxytocin remains the first-line uterotonic agent, with methylergonovine reserved for refractory cases rather than routine prophylaxis. 6

Critical Safety Considerations

  • Avoid methylergometrine in women with hypertension, preeclampsia, cardiovascular disease, or any condition where vasoconstriction poses risk. 4

  • Side effects are generally mild when they occur, but the cardiovascular risks necessitate careful patient selection. 2

  • The maximum treatment duration should not exceed one week postpartum to minimize cumulative adverse effects. 1

References

2
Research

Methylergometrine: comparison of plasma concentrations and clinical response of two brands.

International journal of clinical pharmacology and biopharmacy, 1978

4
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

5
Research

The role of oral (methyl)ergometrine in the prevention of postpartum haemorrhage.

European journal of obstetrics, gynecology, and reproductive biology, 1996

Related Questions

What is the recommended dose of a 0.125 mg Methergine (methylergometrine) tablet for treating uterine atony?
What is the best next step in managing a postpartum woman with persistent vaginal bleeding, a firm uterine fundus, and mild anemia (low hemoglobin), following a forceps-assisted vaginal delivery with a third-degree perineal laceration?
What is the cause of profuse vaginal bleeding in a 27-year-old woman, gravida 2 para 1, at 40 weeks gestation, with a history of preeclampsia with severe features, who underwent a forceps-assisted vaginal delivery and has a firm, nontender uterus with a right vaginal sidewall defect?
What is the most appropriate next step in managing a patient with a densely adherent placenta to the anterior uterine wall after a repeat cesarean delivery (C-section)?
What is the best next step in managing a postpartum woman with severe vaginal bleeding, uterine atony, and tachycardia, unresponsive to uterine massage and high-dose oxytocin?
Is N‑acetylcysteine appropriate for an adult with a productive (wet) cough such as acute bronchitis, and what are the recommended dosage, duration, and safety considerations?
What is the recommended dose of a 0.125 mg Methergine (methylergometrine) tablet for treating uterine atony?
What are the strengths and weaknesses of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM‑5‑TR) and the International Classification of Diseases, Eleventh Revision (ICD‑11) in diagnosing hallucinogen‑related disorders?
Are there any safety concerns when combining clopidogrel with omega‑3 fatty acid (fish‑oil) supplements?
What is the malignancy risk for a 62‑year‑old asymptomatic patient with biopsy‑proven membranous nephropathy diagnosed three years ago, dual positive for anti‑phospholipase A2 receptor (anti‑PLA2R) and anti‑thrombospondin type‑1 domain‑containing 7A (anti‑THSD7A) antibodies, who has relapsed twice and responded to rituximab?
What are the diagnostic changes for inhalant‑related disorders across the Diagnostic and Statistical Manual of Mental Disorders (DSM) versions III, III‑R, IV, V, V‑TR, and the International Classification of Diseases (ICD) versions X and XI?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question